| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.08. | WORK Medical Technology Group LTD - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 17.08. | WORK Medical Technology Group reports Q2 results | 2 | Seeking Alpha | ||
| 16.06. | WORK Medical announces 1-for-100 reverse stock split | 7 | Seeking Alpha | ||
| 16.06. | WORK Medical Technology Group LTD: WORK Medical Announces 1-for-100 Reverse Stock Split Effective June 18, 2026 | 723 | GlobeNewswire (Europe) | Auckland, New Zealand, June 16, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, today announced... ► Artikel lesen | |
| WORK MEDICAL TECHNOLOGY GROUP Aktie jetzt für 0€ handeln | |||||
| 05.06. | WORK Medical Technology Group LTD - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 03.06. | Work Medical establishes U.S. subsidiary in Nevada | 4 | Investing.com | ||
| 03.06. | WORK Medical Technology Group LTD: WORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy | 478 | GlobeNewswire (Europe) | Hangzhou, China, June 03, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) ("WORK Medical", the "Company" or "we"), a supplier of medical devices in China today announced the... ► Artikel lesen | |
| 27.05. | WORK Medical Technology Group LTD - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 14.05. | Morning Market Movers: Robo.ai, Antelope Enterprise Holdings, WORK Medical Technology Group, POET Technologies See Big Swings | 1.538 | AFX News | SAN FRANCISCO (dpa-AFX) - At 8:20 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the... ► Artikel lesen | |
| 11.05. | WORK Medical Technology Group LTD: WORK Medical Collaborates with Novabioplus to Unlock Biological Data Value with AI, Advancing the "BioToken" Assetization Model | 214 | GlobeNewswire (Europe) | Hangzhou, China, May 11, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) ("WORK Medical", the "Company" or "we"), a supplier of medical devices in China, through its subsidiaries... ► Artikel lesen | |
| 29.12.25 | WORK Medical Technology Group LTD: WORK Medical Grants East China Exclusive Distribution Rights for AI-Automated Blood Cell Morphology Analyzer, Sets RMB10 Million Sales Target for 2026 | 718 | GlobeNewswire (Europe) | Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) ("WORK Medical", the "Company" or "we"), a supplier of medical devices in China, through its subsidiary... ► Artikel lesen | |
| 29.12.25 | WORK Medical Technology Group LTD Subsidiary Obtains Manufacturing Approval for Its AI-Automated Blood Cell Morphology Analyzer | 422 | GlobeNewswire (Europe) | Hangzhou, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary... ► Artikel lesen | |
| 24.12.25 | WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025 | 1.178 | GlobeNewswire (Europe) | Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) ("WORK Medical" or the "Company"), a supplier of medical devices in China, through its subsidiary... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 7,088 | -0,34 % | Truist raises Teladoc stock price target to $9 on EBITDA outlook | ||
| SERNOVA BIOTHERAPEUTICS | 0,059 | -9,76 % | Sernova Biotherapeutics: 11,2 Millionen Dollar für die Fusion - und doch rutscht die Aktie | ||
| CERENOME | 0,585 | +23,55 % | Cerenome outlines $10M-$12.5M 2026 gross billings run rate exit while targeting mid-2027 REYOBIQ top line data | ||
| ATOSSA THERAPEUTICS | 1,640 | +2,50 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Nov. 10, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: Rekord bei Umsatz und Gewinn - lächerliche Bewertung! | Sonoma Pharmaceuticals macht den nächsten gewaltigen Schritt auf dem Weg zum profitablen Wachstumsunternehmen. Nach dem erstmaligen Erreichen eines positiven EBITDA im Vorquartal meldet der Healthcare-Spezialist... ► Artikel lesen | |
| TANDEM DIABETES | 15,500 | +0,65 % | Warum die Aktie von Tandem Diabetes Care heute kräftig zulegt | ||
| CO-DIAGNOSTICS | 0,163 | -1,22 % | Co-Diagnostics kündigt Aktienzusammenlegung im Verhältnis 1 zu 25 an | ||
| QUIDELORTHO | 8,994 | +10,74 % | QuidelOrtho Corporation: QuidelOrtho Reports Second Quarter 2026 Financial Results | ? Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth ?
? Excluding China, total revenue grew 6% both as... ► Artikel lesen | |
| VERU | 2,110 | 0,00 % | Veru presents data on enobosarm for obesity treatment | ||
| LIFEWARD | 2,930 | 0,00 % | Lifeward GAAP EPS of -$1.32 misses by $0.50, revenue of $5.43M misses by $1.81M | ||
| CLOVER HEALTH INVESTMENTS | 3,470 | +1,17 % | CLOVER HEALTH INVESTMENTS, CORP. /DE - 8-K, Current Report | ||
| SENSEONICS | 8,800 | +8,64 % | Senseonics Holdings, Inc.: Senseonics and Beta Bionics Launch Eversense 365 and iLet Bionic Pancreas Integration | ||
| TEMPEST THERAPEUTICS | 0,307 | +0,20 % | Tempest Therapeutics GAAP EPS of -$0.21 beats by $0.11 | ||
| NANO-X IMAGING | 0,230 | -0,04 % | NANO-X IMAGING LTD: Nanox to Showcase Its Innovative Technology and Advances Across Nanox.ARC X and Nanox.AI at RSNA 2026 | ||
| IMUNON | 0,400 | -9,09 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |